Sugi Predict

Sugi Predict / Targets / DDT

DDT

D-dopachrome decarboxylase · P30046 · DDT on Sugi Atlas →

1,423 patent compounds predicted against DDT, 934 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3116253 SCHEMBL3116253 0.58 3/20
SCHEMBL12522014 SCHEMBL12522014 0.58 3/20
SCHEMBL70647 SCHEMBL70647 0.57 3/20
SCHEMBL3117451 SCHEMBL3117451 0.54 3/20
SCHEMBL17276510 SCHEMBL17276510 0.53 3/20
SCHEMBL5244424 SCHEMBL5244424 0.52 3/20
SCHEMBL3469839 SCHEMBL3469839 0.51 3/20
SCHEMBL4507183 SCHEMBL4507183 0.50 3/20
SCHEMBL5244307 SCHEMBL5244307 0.50 3/20
SCHEMBL5904691 SCHEMBL5904691 0.44 3/20
SCHEMBL17132812 SCHEMBL17132812 0.39 3/20
SCHEMBL3107534 SCHEMBL3107534 0.62 2/20
SCHEMBL5758687 SCHEMBL5758687 0.60 2/20
SCHEMBL5440472 SCHEMBL5440472 0.56 2/20
SCHEMBL5757082 SCHEMBL5757082 0.54 2/20
SCHEMBL8204104 SCHEMBL8204104 0.54 2/20
SCHEMBL12853297 SCHEMBL12853297 0.53 2/20
SCHEMBL12853538 SCHEMBL12853538 0.52 2/20
SCHEMBL5440126 SCHEMBL5440126 0.51 2/20
SCHEMBL17390464 SCHEMBL17390464 0.51 2/20

Clinical trials — most relevant to DDT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Dopamin Level in Idiopathic Parkinson's Patients PHASE4UNKNOWN
A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts PHASE4WITHDRAWN
Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia PHASE3COMPLETED
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease. PHASE1/PHASE2RECRUITING
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration PHASE2WITHDRAWN
Ambroxol in Disease Modification in Parkinson Disease PHASE2COMPLETED
Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia PHASE2COMPLETED
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease PHASE2COMPLETED
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease PHASE2COMPLETED
Dopaminergic restauratIon by intraVEntriculaire Administration PHASE1/PHASE2COMPLETED
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal PHASE2COMPLETED
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) PHASE2COMPLETED
Mucuna Pruriens Therapy in Parkinson's Disease PHASE2COMPLETED
Pharmacogenetics of Disulfiram for Cocaine PHASE2COMPLETED
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease PHASE1COMPLETED
Lu AF28996 in Participants With Parkinson's Disease (PD) PHASE1COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients EARLY_PHASE1SUSPENDED
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency nanUNKNOWN
The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders. nanENROLLING_BY_INVITATION
Pesticide Exposure and Health Status in North Carolina African American Male Farmers and Farm Workers nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease. nanUNKNOWN
Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls nanSUSPENDED
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography nanCOMPLETED
Prevalence of DAO (diamino Oxidase) Deficiency in Newborns nanCOMPLETED
Breast Cancer, Breast Disease, and Pesticides nanCOMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso nanCOMPLETED
Vancomycin Associated Red Man Syndrome (RMS) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DDT binder may also engage these)

ProteinNameSimilarity
O35215 — 1.000 O35215 →
Q640C5 — 0.995 Q640C5 →
A5PK65 — 0.995 A5PK65 →
Q68FI3 — 0.995 Q68FI3 →
Q5ZMG0 — 0.994 Q5ZMG0 →
P80254 — 0.994 P80254 →
Q28J83 — 0.991 Q28J83 →
Q18785 — 0.983 Q18785 →
O44786 — 0.979 O44786 →
P94502 — 0.975 P94502 →
O34882 — 0.972 O34882 →
Q963F7 — 0.970 Q963F7 →
Q9R061 — 0.967 Q9R061 →
Q9PIM5 — 0.967 Q9PIM5 →
Q8Y183 — 0.967 Q8Y183 →
A0A4V1DXC3 — 0.967 A0A4V1DXC3 →
O24210 — 0.966 O24210 →
O86237 — 0.966 O86237 →
PKLR Pyruvate kinase PKLR 0.966 landscape →
P22989 — 0.966 P22989 →
B9KHF1 — 0.965 B9KHF1 →
Q9HE15 — 0.965 Q9HE15 →
Q5PBX6 — 0.965 Q5PBX6 →
Q8LR50 — 0.965 Q8LR50 →
Q1LJM9 — 0.965 Q1LJM9 →
A0A7T8J1Z8 — 0.965 A0A7T8J1Z8 →
P53657 — 0.965 P53657 →
P38095 — 0.964 P38095 →
Q05354 — 0.964 Q05354 →
O75891 — 0.964 O75891 →